A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by MarketWatch Top; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories
Why it mattersS&P 500 companies’ earnings are mostly topping analysts’ estimates — but by the narrowest margin in roughly four years.
By Michael·32m ago'/> </pattern> </defs> <rect width='1200' height='675' fill='url(%23g)'/> <rect width='1200' height='675' fill='url(%23dots)'/> <rect x='60' y='210' width='6' height='80' fill='%23f5a524'/> <text x='90' y='268' font-size='15' font-weight='900' letter-spacing='5' fill='%23f5a524'>MARKETS</text> <g font-family='Inter, Arial, sans-serif'> <text x='60' y='320' font-size='44' font-weight='800' fill='rgba(255,255,255,0.97)' letter-spacing='-0.5'>Oil Falls on Unconfirmed Report That</text><text x='60' y='376' font-size='44' font-weight='800' fill='rgba(255,255,255,0.97)' letter-spacing='-0.5'>Iran Eased Hormuz Demands</text> <text x='60' y='620' font-size='14' font-weight='700' letter-spacing='3' fill='rgba(255,255,255,0.7)'>BLOOMBERG MARKETS · NEWSEZE</text> </g> </svg>)
Why it mattersOil fell on an unconfirmed report that Iran had made concessions on its demands over the Strait of Hormuz as diplomatic efforts to end the war in the Middle East continue.
By Michael·2h ago
Why it mattersJensen Huang will remain in his role and cooperate with the investigation, though analysts say the matter could cloud over Nvidia’s stock for some time.
By Michael·15h agoWhy it matters“Today’s news will not slow Nvidia,” a spokesperson says. Huang will remain in his role and cooperate with the investigation.
By Michael·16h ago